SPOREGEN LIMITED is a biotechnology company based at The London BioScience Innovation Centre (LBIC) in London. SPOREGEN is focused on four areas. 1. Clostridium difficile: we have developed a unique prophylactic and therapeutic approach for C. difficile infection. 2. Probiotics: we identify and develop Bacillus, heat stable, spore probiotic formulations. This includes progression to GRAS status and a number of these have now been licenced including HU58 and HU36. 3. Prophylactic approaches to COVID-19 including SPOR-COV, a unique mucosal immune modulator, and SPORCOVAX, a mucosal vaccine. 4. Contracts: focusing primarily on in vivo evaluations of C. difficile interventions.